Your browser doesn't support javascript.
loading
Prolonged and tunable residence time using reversible covalent kinase inhibitors.
Bradshaw, J Michael; McFarland, Jesse M; Paavilainen, Ville O; Bisconte, Angelina; Tam, Danny; Phan, Vernon T; Romanov, Sergei; Finkle, David; Shu, Jin; Patel, Vaishali; Ton, Tony; Li, Xiaoyan; Loughhead, David G; Nunn, Philip A; Karr, Dane E; Gerritsen, Mary E; Funk, Jens Oliver; Owens, Timothy D; Verner, Erik; Brameld, Ken A; Hill, Ronald J; Goldstein, David M; Taunton, Jack.
Afiliação
  • Bradshaw JM; Principia Biopharma, South San Francisco, California, USA.
  • McFarland JM; Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco, California, USA.
  • Paavilainen VO; Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco, California, USA.
  • Bisconte A; Principia Biopharma, South San Francisco, California, USA.
  • Tam D; Principia Biopharma, South San Francisco, California, USA.
  • Phan VT; Principia Biopharma, South San Francisco, California, USA.
  • Romanov S; Nanosyn Inc., Santa Clara, California, USA.
  • Finkle D; Principia Biopharma, South San Francisco, California, USA.
  • Shu J; Principia Biopharma, South San Francisco, California, USA.
  • Patel V; Principia Biopharma, South San Francisco, California, USA.
  • Ton T; Principia Biopharma, South San Francisco, California, USA.
  • Li X; Principia Biopharma, South San Francisco, California, USA.
  • Loughhead DG; Principia Biopharma, South San Francisco, California, USA.
  • Nunn PA; Principia Biopharma, South San Francisco, California, USA.
  • Karr DE; Principia Biopharma, South San Francisco, California, USA.
  • Gerritsen ME; Principia Biopharma, South San Francisco, California, USA.
  • Funk JO; Principia Biopharma, South San Francisco, California, USA.
  • Owens TD; Principia Biopharma, South San Francisco, California, USA.
  • Verner E; Principia Biopharma, South San Francisco, California, USA.
  • Brameld KA; Principia Biopharma, South San Francisco, California, USA.
  • Hill RJ; Principia Biopharma, South San Francisco, California, USA.
  • Goldstein DM; Principia Biopharma, South San Francisco, California, USA.
  • Taunton J; Department of Cellular and Molecular Pharmacology and Howard Hughes Medical Institute, University of California, San Francisco, California, USA.
Nat Chem Biol ; 11(7): 525-31, 2015 Jul.
Article em En | MEDLINE | ID: mdl-26006010
ABSTRACT
Drugs with prolonged on-target residence times often show superior efficacy, yet general strategies for optimizing drug-target residence time are lacking. Here we made progress toward this elusive goal by targeting a noncatalytic cysteine in Bruton's tyrosine kinase (BTK) with reversible covalent inhibitors. Using an inverted orientation of the cysteine-reactive cyanoacrylamide electrophile, we identified potent and selective BTK inhibitors that demonstrated biochemical residence times spanning from minutes to 7 d. An inverted cyanoacrylamide with prolonged residence time in vivo remained bound to BTK for more than 18 h after clearance from the circulation. The inverted cyanoacrylamide strategy was further used to discover fibroblast growth factor receptor (FGFR) kinase inhibitors with residence times of several days, demonstrating the generalizability of the approach. Targeting of noncatalytic cysteines with inverted cyanoacrylamides may serve as a broadly applicable platform that facilitates 'residence time by design', the ability to modulate and improve the duration of target engagement in vivo.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acrilamidas / Proteínas Tirosina Quinases / Linfócitos B / Cianoacrilatos / Inibidores de Proteínas Quinases Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acrilamidas / Proteínas Tirosina Quinases / Linfócitos B / Cianoacrilatos / Inibidores de Proteínas Quinases Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article